Nanotechnology breakthrough may boost treatment for aggressive breast cancer: Study

SYDNEY: Researchers in Australia are developing next-generation nanoparticles to supercharge current treatments for triple-negative breast cancer (TNBC) -- one of the most aggressive and deadly forms of the disease.

The researchers are designing innovative iron-based nanoparticles, or "nano-adjuvants," small enough to fit thousands on a single strand of hair, to strengthen the body's immune response against TNBC, according to the University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) on Monday, Xinhua news agency reported.

Unlike other breast cancers, TNBC lacks the proteins targeted by some of the conventional treatments used against other cancers, making effective therapy a significant challenge, according to Prof. Yu Chengzhong from the AIBN.

"Despite the promise of immunotherapy, its effectiveness against triple-negative breast cancer is extremely limited, which is leaving too many women without options -- and that's what our research is trying to change," Yu said.

The nanoparticles are designed to enhance the activity of T-cells, the white blood cells used by the immune system to fight disease, within the tumour microenvironment, improving the immune system's ability to recognise and attack cancer cells, according to Yu.

Supported by a 3 million Australian dollar ($1.89 million) National Health and Medical Research Council grant, the five-year research project aims to bridge a critical treatment gap, and could pave the way for clinical applications, not only for TNBC but also for other hard-to-treat cancers like ovarian cancer.

With over two decades of experience in nanotechnology and nanomedicine, Yu hopes this breakthrough will transform cancer treatment by making immunotherapy more effective for patients with aggressive solid tumours.

"This research will push the boundaries of science to find innovative treatments that change the way we fight this cancer, offering hope for women facing devastating outcomes," said AIBN Director Alan Rowan.